Thomas B. Neff Sells 38,636 Shares of FibroGen, Inc (FGEN) Stock

FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction that occurred on Friday, June 16th. The stock was sold at an average price of $29.40, for a total value of $1,135,898.40. Following the completion of the transaction, the chief executive officer now directly owns 3,330,780 shares in the company, valued at $97,924,932. The sale was disclosed in a legal filing with the SEC, which is available through this link.

FibroGen, Inc (FGEN) opened at 30.15 on Wednesday. FibroGen, Inc has a 52-week low of $14.50 and a 52-week high of $31.25. The company’s market cap is $2.11 billion. The company has a 50-day moving average of $27.99 and a 200 day moving average of $25.07.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. The company had revenue of $26.89 million for the quarter, compared to analyst estimates of $26.02 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. Equities research analysts predict that FibroGen, Inc will post ($1.81) EPS for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Mideast Time and is the sole property of of Mideast Time. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.mideasttime.com/thomas-b-neff-sells-38636-shares-of-fibrogen-inc-fgen-stock/1798558.html.

Separately, Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. FibroGen currently has an average rating of “Buy” and an average price target of $37.50.

Several institutional investors have recently modified their holdings of FGEN. Ameritas Investment Partners Inc. acquired a new position in shares of FibroGen during the first quarter worth approximately $111,000. Airain ltd acquired a new position in shares of FibroGen during the first quarter worth approximately $236,000. Parametric Portfolio Associates LLC acquired a new position in shares of FibroGen during the first quarter worth approximately $249,000. UBS Asset Management Americas Inc. acquired a new position in shares of FibroGen during the first quarter worth approximately $288,000. Finally, Clinton Group Inc. acquired a new position in shares of FibroGen during the first quarter worth approximately $297,000. Institutional investors own 43.85% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:FGEN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.